Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, First-in-Human, Open-Label, Dose Escalation Study of LM-102 Injection in Subjects With CLDN18.2-Positive Advanced Solid Tumors

NCT04735796 is registered in ClinicalTrials.gov with LaNova Medicines Limited as lead sponsor.

NCT NCT04735796
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04735796 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, First-in-Human, Open-Label, Dose Escalation Study of LM-102 Injection in Subjects With CLDN18.2-Positive Advanced Solid Tumors
Lead sponsor
LaNova Medicines Limited
Phase
Phase 1
Overall status
Terminated
Start date
May 27, 2021
Completion date
May 19, 2022
Enrollment
9 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors